David W. Rose

David W. Rose

Auto-generated profile, based on publicly available information

David W. Rose

Howard Hughes Medical Institute, ¶Cellular and Molecular Medicine, ‡Whittier Diabetes Program, and †UCSD Graduate Program in Biology, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648; and §Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284-7884

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RLRobert M. Lavinsky
Robert M. Lavinsky
KJKristen Jepsen
Kristen Jepsen
THThorsten Heinzel
Thorsten Heinzel
JTJoseph Torchia
Joseph Torchia
TMTina-Marie Mullen
Tina-Marie Mullen
DRDavid W. Rose
David W. Rose
Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain. Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways. Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.